Valuation: LigaChem Biosciences Inc.

Market Cap 2,152B 1.58B 1.42B 1.29B 1.18B 2.22B 148B 2.29B 15.59B 6.22B 79.15B 5.92B 5.8B 250B P/E 2026 *
-19.9x
P/E 2027 * -50.2x
Enterprise Value 1.82B 1.33M 1.19M 1.09M 997K 1.88M 125M 1.94M 13.16M 5.25M 66.82M 5M 4.89M 211M EV / Sales 2026 *
12.8x
EV / Sales 2027 * 6.31x
Free-Float
70.31%
Yield 2026 *
-
Yield 2027 * -
10-16 Ligachem Biosciences Co., Ltd. Completes First Patient Administration In Global Phase 1/2 Clinical Trial Of LCB02A CI
08-14 LigaChem Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-24 LigaChem Biosciences Inc. announced that it has received KRW 499.9996776 billion in funding from a group of investors CI
06-24 LigaChem Biosciences Inc. announced that it expects to receive KRW 499.9997309 billion in funding from Pan Orion Corp. Ltd. and other investors CI
05-15 LigaChem Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-25 LigaChem Biosciences Inc.'s Equity Buyback announced on March 25, 2025, has expired with 68,532 shares, representing 0.19% for KRW 6,996.19 million. CI
03-25 Tranche Update on LigaChem Biosciences Inc.'s Equity Buyback Plan announced on March 25, 2025. CI
03-25 Tranche Update on LigaChem Biosciences Inc.'s Equity Buyback Plan announced on March 25, 2025. CI
03-25 Tranche Update on LigaChem Biosciences Inc.'s Equity Buyback Plan announced on March 25, 2025. CI
03-25 Tranche Update on LigaChem Biosciences Inc.'s Equity Buyback Plan announced on March 25, 2025. CI
03-23 LigaChem Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-25 1ST Biotherapeutics, Inc. announced that it has received KRW 31.7 billion in funding from a group of investors CI
01-23 Nextcure, Inc. Provides Updates for Its Two Antibody Drug Conjugate Programs CI
1 day-8.46%
1 week-8.75%
Current month-5.04%
1 month-29.04%
3 months-46.67%
6 months-67.82%
Current year-66.38%
1 week 55,400
Extreme 55400
67,800
1 month 55,400
Extreme 55400
86,200
Current year 55,400
Extreme 55400
225,000
1 year 55,400
Extreme 55400
225,000
3 years 40,500
Extreme 40500
225,000
5 years 30,050
Extreme 30050
225,000
10 years 11,525
Extreme 11525
225,000
Manager TitleAgeSince
Chief Executive Officer 64 2026-04-28
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 2024-10-21
Director TitleAgeSince
Chairman 70 2026-04-28
Director/Board Member 64 2007-06-30
Director/Board Member 66 -
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/24 Buy

Director

940 0.0026%
6/23/24 Buy

Director

940 0.0026%
4/1/24 Sell

Chairman

1,200,000 4.2674%
Change 5-day change 1-year change 3-year change Capi.($)
-8.46%-8.75%-61.58%+49.94% 1.74B
-4.83%+2.88%+55.87%+69.12% 69.4B
+0.02%+1.07%+10.63%+76.66% 57.24B
-1.34%+2.98%+24.79%+100.18% 57.62B
+2.64%+2.28%+29.67%+37.82% 43.65B
+4.91%+10.45%+23.07%+108.54% 44.03B
+8.45%+1.75%+217.14%+803.71% 38.08B
-1.86%+11.46%+26.67%+61.40% 36.31B
-2.97%-9.84%+88.86%+76.17% 32.61B
-2.18%+5.68%+36.21%-0.69% 25.47B
Average -0.55%+1.48%+45.13%+138.28% 40.62B
Weighted average by Cap. +0.04%+2.40%+52.14%+139.78%

Financials

2026 *2027 *
Net sales 142B 104M 93.22M 85.19M 77.77M 147M 9.77B 151M 1.03B 409M 5.21B 390M 382M 16.46B 288B 211M 189M 173M 158M 297M 19.82B 307M 2.08B 831M 10.58B 791M 775M 33.39B
Net income -108B -79.56M -71.36M -65.21M -59.53M -112M -7.48B -116M -786M -313M -3.99B -299M -292M -12.6B -42.09B -30.86M -27.68M -25.3M -23.09M -43.51M -2.9B -44.88M -305M -122M -1.55B -116M -113M -4.89B
Net Debt -335B -246M -220M -201M -184M -347M -23.11B -357M -2.43B -968M -12.33B -923M -903M -38.92B -338B -248M -222M -203M -185M -349M -23.29B -360M -2.45B -976M -12.43B -930M -910M -39.24B
Projected Income Statement - Annual - LigaChem Biosciences Inc.
Logo LigaChem Biosciences Inc.
LigaChem Biosciences Inc, formerly LegoChem Biosciences Inc, is a Korea-based company mainly engaged in development and discovery of new pharmaceuticals based on medical chemistry. The Company principally involves in the development of new drugs, including antibiotics, anticoagulants, anticancer, antiplatelet, anti-inflammatory, as well as antibody-drug-conjugates (ADC), among others. The Company provides technology transfer, joint and contact research and research services. In addition, the Company sells medical devices, medical supplies, prescription drugs, and over the counter (OTC) drugs.
Employees
183
Date Price Change Volume
26-11-05 ₩58,400.00 -8.46% 256,080
26-11-05 ₩63,800.00 +7.41% 411,675
26-11-04 ₩59,400.00 -0.83% 340,084
26-11-03 ₩59,900.00 -2.92% 139,226
26-11-02 ₩61,700.00 +0.33% 112,350
Trader
Investor
-
Global
-
Quality
ESG MSCI
CCC
MarketScreener Ratings - LigaChem Biosciences Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
58,400.00KRW
Average target price
208,000.00KRW
Spread / Average Target
+256.16%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - LigaChem Biosciences Inc.
  1. Stock Market
  2. Stocks
  3. A141080 Stock